Skip to main content
SpringerLink
Log in

Herbal Medicines and Sleep

  • Chapter
Sleep and Sleep Disorders

  • 2156 Accesses

Conclusions

There are several herbs that have central depressant effects and have been used for anxiolytic and sedative effects historically. This has been supported by neuropharmacological, animal, and human studies. Kava, valerian, and passionflower have been the best supported by research in this regard, although others show potential. Much work remains to be done in further testing the safety and efficacy of these drugs. However, with further study some of these medicines may prove favorable in the treatment of sleep-related conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kowalchik C, Hylton WH. In: Emmaus PA, ed. Rodale’s Illustrated Encyclopedia of Herbs Rodale Press, 1987.

    Google Scholar 

  2. Temkin O. The Falling Sickness: A History of Epilepsy from the Greeks to the Beginnings of Modern Neurology. Baltimore: Johns Hopkins University Press, 1971.

    Google Scholar 

  3. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale NJ: Medical Economics Company, 1998.

    Google Scholar 

  4. Houghton PJ. The biological activity of Valerian and related plants. J Ethnopharmacol 1988; 22(2):121–42.

    Article  CAS  PubMed  Google Scholar 

  5. Tyler V. Herbs of Choice. New York: Pharmaceutical Products Press, 1994.

    Google Scholar 

  6. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989; 32(4):1065–6.

    Article  CAS  PubMed  Google Scholar 

  7. Santos MS, Ferreira F, Cunha AP et al. Synaptosomal GABA release as influenced by valerian root extract—involvement of the GABA carrier. Arch Int Pharmacodyn Ther 1994; 327(2):220–31.

    CAS  PubMed  Google Scholar 

  8. Santos MS, Ferreira F, Cunha AP et al. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med 1994; 60(3):278–9.

    Article  CAS  PubMed  Google Scholar 

  9. Santos MS, Ferreira F, Faro C et al. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H]GABA release in synaptosomes. Planta Med 1994; 60(5):475–6. No abstract available.

    Article  CAS  PubMed  Google Scholar 

  10. Yuan CS, Mehendale S, Xiao Y et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg Feb 2004; 98(2):353–8

    Article  CAS  Google Scholar 

  11. Cavadas C, Araujo I, Cotrim MD et al. In vitro study on the interaction of Valeriana officinalis L. Extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung 1995; 45(7):753–5.

    CAS  PubMed  Google Scholar 

  12. Riedel et al. 1982.

    Google Scholar 

  13. Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999; 24(11):1373–8.

    Article  CAS  PubMed  Google Scholar 

  14. Wasowski C, Marder M, Viola H et al. Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA(A) receptors, from Valeriana wallichii. Planta Med 2002; 68(10):934–6.

    Article  CAS  PubMed  Google Scholar 

  15. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999; 51(5):505–12.

    Article  CAS  PubMed  Google Scholar 

  16. Hazelhoff B, Malingre TM, Meijer DK. Antispasmodic effects of valeriana compounds: An in-vivo and in-vitro study on the guinea-pig ileum. Arch Int Pharmacodyn Ther 1982; 257(2):274–87.

    CAS  PubMed  Google Scholar 

  17. Dunaev VV, Trzhetsinskii SD, Tishkin VS et al. Biological activity of the sum of the valepotriates isolated from Valeriana alliariifolia. Farmakol Toksikol 1987; 50(6):33–7.

    CAS  PubMed  Google Scholar 

  18. Holzl J, Fink C. Effect of valeprotriate on spontaneous motor activity in mice. Arzneimittelforschung 1984; 34(1):44–7.

    CAS  PubMed  Google Scholar 

  19. Della Logia R, Tubaro A, Redaelli C. Evaluation of he activity on the mouse CNS of several plant extracts and a combination of them. Riv Neurool 1981; 51(5):297–310.

    Google Scholar 

  20. Leuschner J, Müller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung 1993; 43(6):638–41.

    CAS  PubMed  Google Scholar 

  21. Muller-Limmroth W, Ehrenstein W. Experimental studies of the effects of Seda-Kneipp on the sleep of sleep disturbed subjects; Implications for the treatment of different sleep disturbances (author’s transl). Med Klin 1977; 72(25):1119–25.

    CAS  PubMed  Google Scholar 

  22. Leathwood PD, Chauffard F. Quantifying the effects of mild sedatives. J Psychiatr Res 1982–3; 17(2):115–22.

    Article  PubMed  Google Scholar 

  23. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985; 2:144–8.

    Article  PubMed  Google Scholar 

  24. Balederer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology (Berl) 1985; 87(4):406–9.

    Article  Google Scholar 

  25. Gessner B, Klasser M. Studies on the effect of harmonicum much on sleep using polygraphic EEG recordings. EEG EMG Z Elektroenzephalogr Verwandte Geb 1984; 15(1):45–51.

    CAS  PubMed  Google Scholar 

  26. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: A pilot study. Pharmacopsychiatry 1994; 27(4):147–51.

    Article  CAS  PubMed  Google Scholar 

  27. Herrera-Arellano A, Luna-Villegas G, Cuevas-Uriostegui ML et al. Polysomnographic evaluation of the hypnotic effect of Valeriana edulis standardized extract in patients suffering from insomnia. Planta Med Nov 2001; 67(8):695–9.

    Article  CAS  Google Scholar 

  28. Hadley S, Petry JJ. Valerian. Am Fam Physician 2003; 67(8):1755–8.

    PubMed  Google Scholar 

  29. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989; 32(4):1065–6.

    Article  CAS  PubMed  Google Scholar 

  30. Leathwood PD, Chauffard F, Heck E et al. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982; 17(1):65–71.

    Article  CAS  PubMed  Google Scholar 

  31. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001; 15(6):549–51.

    Article  CAS  PubMed  Google Scholar 

  32. Poyares DR, Guilleminault C, Ohayon MM et al. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(3):539–45.

    Article  CAS  PubMed  Google Scholar 

  33. Francis AJ, Dempster RJ. Effect of valerian, Valeriana edulis, on sleep difficulties in children with intellectual deficits: Randomised trial. Phytomedicine 2002; 9(4):273–9.

    Article  CAS  PubMed  Google Scholar 

  34. Gerhard U, Hobi V, Kocher R et al. Acute sedative effect of a herbal relaxation tablet as compared to that of bromazepam. Schweiz Rundsch Med Prax 1991; 80(52):1481–6.

    CAS  PubMed  Google Scholar 

  35. Hadley S, Petry JJ. Valerian. Am Fam Physician 2003; 67(8):1755–8.

    PubMed  Google Scholar 

  36. Lebot V, Merlin M, Lindstrom L. Kava—the Pacific elixir: The definitive guide to its ethnobotany, history, and chemistry. Rochester, Vt: Healing Arts Press, 1997.

    Google Scholar 

  37. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines. Altern Med Rev 2002; 7(2):130–7.

    PubMed  Google Scholar 

  38. Boonen G, Haberlein H. Influence of genuine kavalactone enantiomers on the GABA-A binding site. Planta Med 1998; 64(6):504–6.

    Article  CAS  PubMed  Google Scholar 

  39. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994; 116(4):469–74.

    Article  CAS  PubMed  Google Scholar 

  40. Davies LP, Drew CA, Duffield P et al. Kava pyrones and resin: Studies on GABAA, GABAB and benzodiazepinebinding sites in rodent brain. Pharmacol Toxicol 1992; 71(2):120–6.

    Article  CAS  PubMed  Google Scholar 

  41. Friese J, Gleitz J. Kavain, dihydrokavain, and dihydromethysticin noncompetitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. Planta Med 1998; 64(5):458–9.

    Article  CAS  PubMed  Google Scholar 

  42. Gleitz J, Friese J, Beile A et al. Anticonvulsive action of (+/−)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996; 315(1):89–97.

    Article  CAS  PubMed  Google Scholar 

  43. Ferger B, Boonen G, Häberlein H et al. In vivo microdialysis study of (+/−)-kavain on veratridine-induced glutamate release. Eur J Pharmacol 1998; 347(2–3):211–4.

    Article  CAS  PubMed  Google Scholar 

  44. Schirrmacher K, Busselberg D, Langosch JM et al. Effects of (+/−)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats. Eur Neuropsychopharmacol 1999; 9(1–2):171–6.

    Article  CAS  PubMed  Google Scholar 

  45. Keledjian J, Duffield PH, Jamieson DD et al. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J Pharm Sci 1988; 77(12):1003–6.

    Article  CAS  PubMed  Google Scholar 

  46. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med 1997; 63(6):548–9.

    Article  CAS  PubMed  Google Scholar 

  47. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry 1998; 31(5):187–92.

    Article  CAS  PubMed  Google Scholar 

  48. Boonen G, Ferger B, Kuschinsky K et al. In vivo effects of the kavalactones (+)-dihydromethysticin and (+/−)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med 1998; 64(6):507–10.

    Article  CAS  PubMed  Google Scholar 

  49. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavalactones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22(7):1105–20.

    Article  CAS  PubMed  Google Scholar 

  50. Frey R. Demonstration of the central effects of D,L-kawain with EEG brain mapping. Fortschr Med 1991; 109(25):505–8.

    CAS  PubMed  Google Scholar 

  51. Münte TF, Heinze HJ, Matzke M et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27(1):46–53.

    Article  PubMed  Google Scholar 

  52. Heinze HJ, Münthe TF, Steitz J et al. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 1994; 27(6):224–30.

    Article  CAS  PubMed  Google Scholar 

  53. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug & Alcohol Review 1997; 16(2):147–155.

    Article  CAS  Google Scholar 

  54. Cairney S, Maruff P, Clough AR et al. Saccade and cognitive impairment associated with kava intoxication. Hum Psychopharmacol 2003; 18(7):525–33.

    Article  PubMed  Google Scholar 

  55. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. J Clin Psychopharmacol 2000; (1):84–9.

    Article  Google Scholar 

  56. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001; 15(6):549–51.

    Article  CAS  PubMed  Google Scholar 

  57. Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord 2004; 78(2):101–10.

    Article  PubMed  Google Scholar 

  58. Almeida JC, Grimsley EW. Coma from the health food store: Interaction between kava and alprazolam. Ann Intern Med 1996; 125(11):940–1.

    CAS  PubMed  Google Scholar 

  59. Stickel F, Baumuller HM, Seitz K et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39(1):62–7.

    Article  CAS  PubMed  Google Scholar 

  60. Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: A randomized placebo-controlled double-blind multicenter trial. Phytomedicine 2003; 10(8):631–9.

    Article  CAS  PubMed  Google Scholar 

  61. Singh YN, Devkota AK. Aqueous kava extracts do not affect liver function tests in rats. Planta Med 2003; 69(6):496–9.

    Article  CAS  PubMed  Google Scholar 

  62. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 2003; 41(6):821–9.

    Article  PubMed  Google Scholar 

  63. Whitton PA, Lau A, Salisbury A et al. Kava lactones and the kava-kava controversy. Phytochemistry 2003; 64(3):673–9.

    Article  CAS  PubMed  Google Scholar 

  64. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31(1):89–97.

    Article  CAS  PubMed  Google Scholar 

  65. Schelosky L, Raffauf C, Jendroska K et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58(5):639–40.

    Article  CAS  PubMed  Google Scholar 

  66. Menghini A, Mancini LA. TLC determination of flavonoid accumulation in clonal populations of Passiflora incarnata L. Pharmacol Res Commun 1988; 20(Suppl 5):113–6.

    Article  CAS  PubMed  Google Scholar 

  67. Medina JH, Paladini AC, Wolfman C et al. Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 1990; 40(10):2227–31.

    Article  CAS  PubMed  Google Scholar 

  68. Medina JH, Paladini AC, Wolfman C et al. Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 1990; 40(10):2227–31.

    Article  CAS  PubMed  Google Scholar 

  69. Zanoli P, Avallone R, Baraldi M. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia 2000; 71(Suppl 1):S117–23.

    Article  CAS  PubMed  Google Scholar 

  70. Goutman JD, Waxemberg MD, Donate-Oliver F et al. Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. Eur J Pharmacol 2003; 461(2–3):79–87.

    Article  CAS  PubMed  Google Scholar 

  71. Wolfman C, Viola H, Paladini A et al. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav 1994; 47(1):1–4.

    Article  CAS  PubMed  Google Scholar 

  72. Maluf E, Baros HMT, Frochtengarten ML et al. Assessment of the hypnotic/sedative effects and toxicity of Passiflora edulis aqueous extract in rodents and humans. Phytother Res 1991; 5(6):262–266.

    Article  Google Scholar 

  73. Dhawan K, Dhawan S, Chhabra S. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: A nonhabit forming anxiolytic.

    Google Scholar 

  74. Akhondzadeh S, Naghavi HR, Vazirian M et al. Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001; 26(5):363–7.

    Article  CAS  PubMed  Google Scholar 

  75. Salgueiro JB, Ardenghi P, Dias M et al. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem Behav 1997; 58(4):887–91.

    Article  CAS  PubMed  Google Scholar 

  76. Medina JH, Viola H, Wolfman C et al. Overview—flavonoids: A new family of benzodiazepine receptor ligands. Neurochem Res 1997; 22(4):419–25.

    Article  CAS  PubMed  Google Scholar 

  77. Smith GW, Chalmers TM, Nuki G. Vasculitis associated with herbal preparation containing Passiflora extract [letter]. Br J Rheumatol 1993; 32(1):87–8.

    Article  CAS  PubMed  Google Scholar 

  78. Robbers JE, Speedie MK, Tyler VE. Pharmacognosy and Pharmacobiotechnology. Baltimore: Willams and Wilkins, 1996.

    Google Scholar 

  79. Viola H, Wasowski C, Levi de Stein M et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 1995; 61(3):213–6.

    Article  CAS  PubMed  Google Scholar 

  80. Osterhoudt KC, Lee SK, Callahan JM et al. Catnip and the alteration of human consciousness. Vet Hum Toxicol 1997; 39(6):373–5.

    CAS  PubMed  Google Scholar 

  81. Hansel R, Wohlfart R, Coper H. Sedative-hypnotic compounds in the exhalation of hops, II. Z Naturforsch [C] 1980; 35(11–12):1096–7.

    CAS  Google Scholar 

  82. Hansel R, Wagener HH. Attempts to identify sedative-hypnotic active substances in hops. Arzneimittelforschung 1967; 17(1):79–81.

    CAS  PubMed  Google Scholar 

  83. Wong AHC, Smith M, Boon H. Herbal remedies in psychiatrtic practice. Archives of General Psychiatry 1998; 55:1033–44.

    Article  CAS  PubMed  Google Scholar 

  84. Awad R, Arnason JT, Trudeau V et al. Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): A medicinal plant with anxiolytic properties. Phytomedicine 2003; 10(8):640–9.

    Article  CAS  PubMed  Google Scholar 

  85. Wolfson P, Hoffmann DL. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med 2003; 9(2):74–8.

    CAS  PubMed  Google Scholar 

  86. Soulimani R, Fleurentin J, Mortier F et al. Neurotropic action of the hydroalcoholic extract of Melissa officinalis in the mouse. Planta Med 1991; 57(2):105–9.

    Article  CAS  PubMed  Google Scholar 

  87. Kennedy DO, Wake G, Savelev S et al. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology 2003; 28(10):1871–81.

    Article  CAS  PubMed  Google Scholar 

  88. Gupta RK, Moller HJ. St. John’s Wort. An option for the primary care treatment of depressive patients? Eur Arch Psychiatry Clin Neurosci 2003; 253(3):140–8.

    Article  CAS  PubMed  Google Scholar 

  89. Spinella M. The psychopharmacology of herbal medicines: Plant drugs that alter mind, brain, and behavior. MIT Press, 2001.

    Google Scholar 

  90. Butterweck V. Mechanism of action of St John’s wort in depression: What is known? CNS Drugs 2003; 17(8):539–62.

    Article  CAS  PubMed  Google Scholar 

  91. Schellenberg R, Sauer S, Dimpfel W. Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry 1998; 31(Suppl 1):44–53.

    Article  CAS  PubMed  Google Scholar 

  92. Sharpley AL, McGavin CL, Whale R et al. Antidepressant-like effect of Hypericum perforatum (St John’s wort) on the sleep polysomnogram. Psychopharmacology (Berl) 1998; 139(3):286–7.

    Article  CAS  PubMed  Google Scholar 

  93. Markowitz JS, Donovan JL, DeVane CL et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290(11):1500–4.

    Article  CAS  PubMed  Google Scholar 

  94. Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002; 16(4):359–67.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Social and Behavioral Sciences, Richard Stockton College of New Jersey, Pomona, New Jersey, USA

    Marcello Spinella

Authors
  1. Marcello Spinella
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Landes Bioscience/Eurekah.com and Springer Science+Business Media

About this chapter

Cite this chapter

Spinella, M. (2006). Herbal Medicines and Sleep. In: Sleep and Sleep Disorders. Springer, Boston, MA. https://doi.org/10.1007/0-387-27682-3_34

Download citation

Publish with us

Policies and ethics

Search

Navigation